Virginia budget expands Medicaid access to sickle cell gene therapy

Virginia has committed nearly $15 million over two years to expand Medicaid coverage for gene therapy treatments for sickle cell disease, a groundbreaking decision that could greatly improve access to this costly but potentially life-changing treatment. This move aligns with a federal model aimed at helping Medicaid programs cover expensive medical innovations, reflecting a significant shift in how the state addresses healthcare inequities. The expansion is expected to benefit numerous patients who previously faced barriers due to the high cost of gene therapy, highlighting the state's commitment to advancing medical care and addressing health disparities.